{"disease":{"id":"spastic","name":"spastic"},"drugs":{"marketed":[{"drug_id":"onabotulinumtoxina","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Botox","generic_name":"ONABOTULINUMTOXINA","company_name":"Allergan","drug_phase":"marketed","molecular_target":"SNAP-25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":60,"revenue":"5300","mechanism":"BOTOX blocks neuromuscular transmission by inhibiting acetylcholine release through cleavage of SNAP-25."},{"drug_id":"incobotulinumtoxina","indication_name":"Upper limb spasticity in pediatric patients (excluding cerebral palsy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"caduet","indication_name":"Vasospastic Angina (Prinzmetal’s or Variant Angina)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"diazepam","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valium","generic_name":"diazepam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sativex","indication_name":"Muscle Spasticity due to Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sativex","company_name":"Jazz Pharmaceuticals","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"chlorphenesin-carbamate","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maolate","generic_name":"CHLORPHENESIN CARBAMATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"botulinum-toxin-type-a","indication_name":"Lower limb spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuceiva","generic_name":"BOTULINUM TOXIN TYPE A","company_name":"GlaxoSmithKline K.K.","drug_phase":"marketed","molecular_target":"Synaptosomal-associated protein 25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":10,"revenue":null,"mechanism":"Nuceiva works by blocking the release of acetylcholine, a neurotransmitter that transmits signals from nerve cells to muscles, thereby reducing muscle spasms and contractions."},{"drug_id":"botulinum-toxin-type-a","indication_name":"Upper limb spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuceiva","generic_name":"BOTULINUM TOXIN TYPE A","company_name":"GlaxoSmithKline K.K.","drug_phase":"marketed","molecular_target":"Synaptosomal-associated protein 25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":10,"revenue":null,"mechanism":"Nuceiva works by blocking the release of acetylcholine, a neurotransmitter that transmits signals from nerve cells to muscles, thereby reducing muscle spasms and contractions."},{"drug_id":"methocarbamol","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Robaxin","generic_name":"METHOCARBAMOL","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1","drug_class":"Muscle Relaxant [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"metaxalone","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Skelaxin","generic_name":"METAXALONE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Muscle Relaxant [EPC]","quality_score":55,"revenue":null,"mechanism":"Skelaxin works by inhibiting the action of neurotransmitters that stimulate muscle contraction."},{"drug_id":"orphenadrine","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norflex","generic_name":"ORPHENADRINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Muscle Relaxant","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"caffeine","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"caffeine","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"verapamil-hydrochloride","indication_name":"Vasospastic (Prinzmetal's variant) angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"tizanidine","indication_name":"Muscle Spasticity of Cerebral Origin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zanaflex","generic_name":"TIZANIDINE","company_name":"Legacy Pharma Usa","drug_phase":"marketed","molecular_target":"Nischarin","drug_class":"Central alpha-2 Adrenergic Agonist","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"tizanidine","indication_name":"Muscle spasticity of spinal origin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zanaflex","generic_name":"TIZANIDINE","company_name":"Legacy Pharma Usa","drug_phase":"marketed","molecular_target":"Nischarin","drug_class":"Central alpha-2 Adrenergic Agonist","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"tizanidine","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zanaflex","generic_name":"TIZANIDINE","company_name":"Legacy Pharma Usa","drug_phase":"marketed","molecular_target":"Nischarin","drug_class":"Central alpha-2 Adrenergic Agonist","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"cannabinoids","indication_name":"Muscle Spasticity due to Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cannabinoids","company_name":"New York State Psychiatric Institute","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"carisoprodol","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Soma","generic_name":"CARISOPRODOL","company_name":"Mylan Speciality Lp","drug_phase":"marketed","molecular_target":"","drug_class":"Muscle Relaxant [EPC]","quality_score":59,"revenue":null,"mechanism":"Carisoprodol's mechanism for relieving acute musculoskeletal pain is unclear, but it involves altered interneuronal activity in the spinal cord and brain."},{"drug_id":"dantrolene","indication_name":"Muscle Spasticity of Cerebral Origin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ryanodex","generic_name":"DANTROLENE","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"Ryanodine receptor 1","drug_class":"Skeletal Muscle Relaxant","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"dantrolene","indication_name":"Muscle spasticity of spinal origin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ryanodex","generic_name":"DANTROLENE","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"Ryanodine receptor 1","drug_class":"Skeletal Muscle Relaxant","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"dantrolene","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ryanodex","generic_name":"DANTROLENE","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"Ryanodine receptor 1","drug_class":"Skeletal Muscle Relaxant","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"chlorzoxazone","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Parafon Forte Dsc","generic_name":"CHLORZOXAZONE","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Nitric oxide synthase, endothelial","drug_class":"Muscle Relaxant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"incobotulinumtoxina","indication_name":"Upper limb spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"incobotulinumtoxina","indication_name":"Upper limb spasticity in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"incobotulinumtoxina","indication_name":"Spasticity caused by cerebral palsy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"baclofen","indication_name":"Muscle Spasticity of Cerebral Origin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lioresal","generic_name":"BACLOFEN","company_name":"","drug_phase":"marketed","molecular_target":"GABA-B receptor","drug_class":"gamma-Aminobutyric Acid-ergic Agonist [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"baclofen","indication_name":"Muscle spasticity of spinal origin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lioresal","generic_name":"BACLOFEN","company_name":"","drug_phase":"marketed","molecular_target":"GABA-B receptor","drug_class":"gamma-Aminobutyric Acid-ergic Agonist [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"cyclobenzaprine","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amrix","generic_name":"CYCLOBENZAPRINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Muscle Relaxant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"incobotulinumtoxina","indication_name":"Upper limb spasticity in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"thiocolchicoside","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Muscoril","generic_name":"THIOCOLCHICOSIDE","company_name":"","drug_phase":"phase_3","molecular_target":"GABA A receptor alpha-1/beta-1/gamma-2, GABA A receptor alpha-2/beta-2/gamma-2, GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":30,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03047369","title":"The Myelin Disorders Biorepository Project","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT01568658","title":"Genetic and Physical Study of Childhood Nerve and Muscle Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":9300,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT04674449","title":"iCorMicA - Stratified Medicine in Angina","phase":"NA","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"NHS Greater Glasgow and Clyde","has_results":false},{"nct_id":"NCT00001156","title":"Assessment of Patients With Multiple Sclerosis (MS)","phase":"","overall_status":"COMPLETED","enrollment_count":1388,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT06055725","title":"A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1058,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT07196397","title":"POLish Registry of CArdioneuroablation and CArdioneuromodulation","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"SABAMED Medical Center Ltd.","has_results":false},{"nct_id":"NCT07103317","title":"Comprehensive Coronary Physiology in Patients With Angina With Nonobstructive Coronary Arteries - Czech Republic","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University Hospital, Motol","has_results":false},{"nct_id":"NCT03999788","title":"miR-142-3p as Potential Biomarker of Synaptopathy in MS","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Neuromed IRCCS","has_results":false},{"nct_id":"NCT06092346","title":"A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":999,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT03893396","title":"Safety Assessment of Angioplasty Procedures","phase":"","overall_status":"COMPLETED","enrollment_count":983,"lead_sponsor_name":"Groupe Hospitalier de la Rochelle Ré Aunis","has_results":true},{"nct_id":"NCT05379413","title":"Observational Longitudinal Study on the Outbreak and Management of Stroke Related Spasticity","phase":"","overall_status":"UNKNOWN","enrollment_count":960,"lead_sponsor_name":"Campus Bio-Medico University","has_results":false},{"nct_id":"NCT03660969","title":"Reliability of Cardiac Troponins for the Diagnosis of Myocardial Infarction in the Presence of Skeletal Muscle Disease","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":797,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT00001778","title":"Evaluation of Patients With HAM/TSP","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT01930786","title":"An Adult Spasticity Registry of OnabotulinumtoxinA Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":744,"lead_sponsor_name":"Allergan","has_results":false},{"nct_id":"NCT04712812","title":"Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Boston Children's Hospital","has_results":false},{"nct_id":"NCT04827498","title":"Myocardial Ischemia Without Obstructive Coronary Stenoses","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Hospital San Carlos, Madrid","has_results":false},{"nct_id":"NCT03588832","title":"Prevalence of Postural Patterns of Upper Extremity.","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Universidad de La Frontera","has_results":false},{"nct_id":"NCT03290131","title":"A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":536,"lead_sponsor_name":"RVL Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07504627","title":"How Stroke Affects Leg Muscles When Walking","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"University Hospital, Limoges","has_results":false},{"nct_id":"NCT06572046","title":"STOP-HSP.Net: a Registry for Hereditary Spastic Paraplegia as an Integration Tool for Future Therapeutic Strategies","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"IRCCS Fondazione Stella Maris","has_results":false},{"nct_id":"NCT04936542","title":"A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":464,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT04649632","title":"Relation Between Dose and Time to Reinjection of Botulinum Toxin-A in Patient With Poststroke Spasticity From a Real-world Healthcare Insurance Database.","phase":"","overall_status":"COMPLETED","enrollment_count":451,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT04050527","title":"Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":438,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT03756974","title":"BX-1 in Spasticity Due to Multiple Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":397,"lead_sponsor_name":"Bionorica SE","has_results":false},{"nct_id":"NCT01457352","title":"Efficacy and Safety of SPARC0921 in Subjects With Spasticity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":392,"lead_sponsor_name":"Sun Pharma Advanced Research Company Limited","has_results":true},{"nct_id":"NCT01603628","title":"BOTOX® Treatment in Pediatric Lower Limb Spasticity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":384,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT07293650","title":"PREcision MEDicine In Achalasia (PREMEDIA)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":372,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT01603641","title":"BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":370,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT00001922","title":"Sensory Function in Idiopathic Voice Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":370,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT02002884","title":"Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":351,"lead_sponsor_name":"Merz Pharmaceuticals GmbH","has_results":true},{"nct_id":"NCT03319732","title":"A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":323,"lead_sponsor_name":"RVL Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05373082","title":"Identification of Modifying Factors in Hereditary Spastic Paraplegia","phase":"","overall_status":"COMPLETED","enrollment_count":311,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07478822","title":"A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Chongqing Claruvis Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06958341","title":"Neuroimmunology Registry and Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT04815967","title":"Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":272,"lead_sponsor_name":"Supernus Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT00001552","title":"Characteristics of Idiopathic Familial Voice Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT06783114","title":"A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":254,"lead_sponsor_name":"Chongqing Claruvis Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03626350","title":"Prospective Evaluation of the Efficacy and Safety of Submucosal Endoscopy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT03017729","title":"Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity","phase":"","overall_status":"COMPLETED","enrollment_count":242,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT04752774","title":"A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT02699190","title":"LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies","phase":"","overall_status":"COMPLETED","enrollment_count":236,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":true},{"nct_id":"NCT01603602","title":"BOTOX® Treatment in Pediatric Upper Limb Spasticity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT01603615","title":"BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT03289702","title":"CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Medy-Tox","has_results":false},{"nct_id":"NCT04714385","title":"Medtronic PSR TDD PMCF","phase":"","overall_status":"COMPLETED","enrollment_count":209,"lead_sponsor_name":"Medtronic","has_results":false},{"nct_id":"NCT05354622","title":"Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Boston Children's Hospital","has_results":false},{"nct_id":"NCT07293689","title":"PREcision MEDicine In Achalasia (PREMEDIA) - Cohort","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT06811142","title":"Early Botulinum Toxin for Muscle Stiffness Reduction in First-Time Stroke Patients: Improving Recovery and Independence","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Instituto Mexicano del Seguro Social","has_results":false},{"nct_id":"NCT06782490","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04446702","title":"Retrospective Real-Life Study From One Brazilian Reference Center Assessing Long-Term Experience In The Treatment Of Adult Spasticity With AbobotulinumtoxinA","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Ipsen","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}